Patents by Inventor Frank Stieber

Frank Stieber has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pyridazinone derivatives
    Patent number: 8859547
    Abstract: Compounds of the formula I in which R1, R2, R3, R4, R4? have the meanings indicated in Claim 1, are inhibitors of tyrosine kinases, in particular Met kinase, and can be employed, inter alia, for the treatment of tumors.
    Type: Grant
    Filed: March 8, 2013
    Date of Patent: October 14, 2014
    Assignee: Merck Patent GmbH
    Inventors: Dieter Dorsch, Oliver Schadt, Frank Stieber, Andree Blaukat
  • Pyridazinone derivatives
    Patent number: 8853211
    Abstract: Compounds of the formula (I) in which D, R1, R2, R3, R4 have the meanings indicated in Claim 1, are inhibitors of tyrosine kinases, in particular of Met kinase, and can be employed, inter alia, for the treatment of tumors.
    Type: Grant
    Filed: December 10, 2009
    Date of Patent: October 7, 2014
    Assignee: Merck Patent GmbH
    Inventors: Dieter Dorsch, Oliver Schadt, Frank Stieber, Andree Blaukat
  • NOVEL POLYMORPHIC FORMS OF 3-(1--6-OXO-1,6-DIHYDRO-PYRIDAZIN-3-YL)-BENZONITRILE HYDROCHLORIDE SALT AND PROCESSES OF MANUFACTURING THEREOF
    Publication number: 20140200221
    Abstract: The present invention relates to 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride solvates and crystalline modifications thereof. The present invention further relates to processes of manufacturing these crystalline modifications as well as their use in the treatment and/or prophylaxis of physiological and/or pathophysiological conditions, which are caused, mediated and/or propagated by the inhibition, regulation and/or modulation of signal transduction of kinases, in particular by the inhibition of tyrosine kinases, e.g. pathophysiological conditions such as cancer.
    Type: Application
    Filed: January 17, 2014
    Publication date: July 17, 2014
    Applicant: MERCK PATENT GMBH
    Inventors: Axel BECKER, Clemens KUEHN, Christoph SAAL, Oliver SCHADT, Dieter DORSCH, Heinz-Hermann BOKEL, Frank STIEBER, Cristina DONINI
  • PYRIDAZINONE DERIVATIVES
    Publication number: 20140148463
    Abstract: Compounds of the formula (I) in which D, R1, R2, R3, R4 have the meanings indicated in Claim 1, are inhibitors of tyrosine kinases, in particular of Met kinase, and can be employed, inter alia, for the treatment of tumours.
    Type: Application
    Filed: January 31, 2014
    Publication date: May 29, 2014
    Inventors: Dieter DORSCH, Oliver SCHADT, Frank STIEBER, Andree BLAUKAT
  • PYRIMIDINYL PYRIDAZINONE DERIVATIVES
    Publication number: 20140128396
    Abstract: Compounds selected from the group according to Claim 1 are inhibitors of tyrosine kinases, in particular of Met kinase, and can be employed, inter alia, for the treatment of tumours.
    Type: Application
    Filed: January 7, 2014
    Publication date: May 8, 2014
    Applicant: Merck Patent GmbH
    Inventors: Oliver SCHADT, Dieter DORSCH, Frank STIEBER, Andree BLAUKAT
  • Polymorphic forms of 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride salt and processes of manufacturing thereof
    Patent number: 8710058
    Abstract: Compounds of the present invention concern 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride solvates and crystalline modifications thereof. The compound, 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile, has the following structural formula: The hydrochloride solvates and crystalline modifications thereof according to the invention are useful for treatment of physiological and/or pathophysiological conditions, such as cancer, that are caused, mediated and/or propagated by the inhibition, regulation and/or modulation of signal transduction of kinases, in particular by the inhibition of tyrosine kinases, especially Met-kinase. The present invention further relates to processes of manufacturing these crystalline modifications.
    Type: Grant
    Filed: December 4, 2009
    Date of Patent: April 29, 2014
    Assignee: MERCK PATENT GmbH
    Inventors: Axel Becker, Clemens Kuehn, Christoph Saal, Oliver Schadt, Dieter Dorsch, Heinz Hermann Bokel, Frank Stieber, Cristina Donini
  • Pyrimidinyl pyridazinone derivatives
    Patent number: 8658643
    Abstract: Compounds selected from the group according to claim 1 are inhibitors of tyrosine kinases, in particular of Met kinase, and can be employed, inter alia, for the treatment of tumours.
    Type: Grant
    Filed: August 3, 2012
    Date of Patent: February 25, 2014
    Assignee: Merck Patent GmbH
    Inventors: Oliver Schadt, Dieter Dorsch, Frank Stieber, Andree Blaukat
  • Amino azaheterocyclic carboxamides
    Patent number: 8637532
    Abstract: The invention provides novel substituted amino azaheterocyclic carboxamide compounds according to Formula (I), their manufacture and use for the treatment of hyperproliferative diseases, such as cancer.
    Type: Grant
    Filed: February 4, 2010
    Date of Patent: January 28, 2014
    Assignee: Merck Patent GmbH
    Inventors: Amanda E. Sutton, Ruoxi Lan, Thomas E. Richardson, David Perrey, Harold George Vandeveer, Bayard R. Huck, Srinivasa R. Karra, Xiaoling Chen, Yufang Xiao, Lesley Liu-Bujalski, Andreas Goutopoulos, Frank Stieber, Brian L. Hodous, Hui Qiu, Reinaldo Jones, Brian H. Heasley
  • Pyridazinone derivatives
    Patent number: 8637518
    Abstract: Compounds of the formula (I), in which Y, R1, R2, R3 and R3? have the meanings indicated in claim 1, are inhibitors of tyrosine kinases, in particular of Met kinase, and can be employed, inter alia, for the treatment of tumours.
    Type: Grant
    Filed: November 24, 2009
    Date of Patent: January 28, 2014
    Assignee: MERCK PATENT GmbH
    Inventors: Frank Stieber, Oliver Schadt, Dieter Dorsch, Andree Blaukat
  • Pyridazinone derivatives
    Patent number: 8623870
    Abstract: Compounds of the formula (I), in which D, R1, R2, R3, R4 have the meanings indicated in Claim 1, are inhibitors of tyrosine kinases, in particular of Met kinase, and can be employed, inter alia, for the treatment of tumors.
    Type: Grant
    Filed: December 10, 2009
    Date of Patent: January 7, 2014
    Assignee: Merck Patent GmbH
    Inventors: Dieter Dorsch, Oliver Schadt, Frank Stieber, Andree Blaukat
  • Pyridazinone derivatives
    Patent number: 8604036
    Abstract: Compounds of the formula (I), in which R1, R2, R3, W and D have the meanings indicated in Claim 1, are inhibitors of tyrosine kinases, in particular of Met kinase, and can be employed, inter alia, for the treatment of tumors.
    Type: Grant
    Filed: March 24, 2009
    Date of Patent: December 10, 2013
    Assignee: Merck Patent GmbH
    Inventors: Dieter Dorsch, Oliver Schadt, Frank Stieber, Andree Blaukat
  • Polymorphic forms of 6-(1-methyl-1H-pyrazol-4-yl)-2-{3-[5-(2-morpholin-4-yl-ethoxy)-pyrimidin-2-yl]-benzyl}-2H-pyridazin-3-one dihydrogenphosphate and processes of manufacturing thereof
    Patent number: 8586599
    Abstract: The present invention relates to 6-(1-methyl-1H-pyrazol-4-yl)-2-{3-[5-(2-morpholin-4-yl-ethoxy)-pyrimidin-2-yl]-benzyl}-2H-pyridazin-3-one dihydrogenphosphate, its solvates and crystalline modifications thereof. The present invention further relates to processes of manufacturing these crystalline modifications as well as their use in the treatment and/or prophylaxis of physiological and/or pathophysiological conditions, which are caused, mediated and/or propagated by the inhibition, regulation and/or modulation of signal transduction of kinases, in particular by the inhibition of tyrosine kinases, e.g. pathophysiological conditions such as cancer.
    Type: Grant
    Filed: November 24, 2009
    Date of Patent: November 19, 2013
    Assignee: Merck Patent GmbH
    Inventors: Axel Becker, Clemens Kuehn, Christoph Saal, Oliver Schadt, Dieter Dorsch, Eva Kriegbaum, Frank Stieber, Cristina Donini
  • Pyridazinone derivatives
    Patent number: 8580781
    Abstract: Compounds of the formula (I), in which R1, R2, R3, R4, R4? have the meanings indicated in claim 1, are inhibitors of tyrosine kinases, in particular Met kinase, and can be employed, inter alia, for the treatment of tumors.
    Type: Grant
    Filed: April 29, 2008
    Date of Patent: November 12, 2013
    Assignee: Merck Patent GmbH
    Inventors: Dieter Dorsch, Frank Stieber, Oliver Schadt, Andree Blaukat
  • 3-(3-pyrimidine-2-yl-benzyl)-[1,2,4] triazolo[4,3-b]pyrimidine derivatives
    Patent number: 8563561
    Abstract: The 3-(3-pyrimidin-2ylbenzyl)-1,2,4-triazolo[4,3-b]pyrimidine compounds of formula in which R1, R2, R3, R3, R4 have the meanings indicated herein, are inhibitors of tyrosine kinases, in particular Met kinase, and can be employed, inter alia, for the treatment of tumors.
    Type: Grant
    Filed: November 18, 2009
    Date of Patent: October 22, 2013
    Assignee: Merck Patent GmbH
    Inventors: Oliver Schadt, Dieter Dorsch, Frank Stieber, Andree Blaukat
  • 2-benzylpyridazinone derivatives as met kinase inhibitors
    Patent number: 8557813
    Abstract: Compounds of the formula I in which R1, R2, R3, R4? have the meanings indicated in claim 1, are inhibitors of tyrosine kinases, in particular Met kinase, and can be employed, inter alia, for the treatment of tumors.
    Type: Grant
    Filed: November 25, 2008
    Date of Patent: October 15, 2013
    Assignee: Merck Patent GmbH
    Inventors: Dieter Dorsch, Oliver Schadt, Frank Stieber, Andree Blaukat
  • 3-(3-pyrimidin-2-ylbenzyl)-1,2,4-triazolo[4,3-b]pyridazine derivatives as MET kinase inhibitors
    Patent number: 8497266
    Abstract: Compounds of the formula (I), in which R1, R2, R3, R3?, R4 have the meanings indicated in Claim 1, are inhibitors of tyrosine kinases, in particular of Met kinase, and can be employed, inter alia, for the treatment of tumors.
    Type: Grant
    Filed: May 25, 2009
    Date of Patent: July 30, 2013
    Assignee: Merck Patent GmbH
    Inventors: Dieter Dorsch, Oliver Schadt, Frank Stieber, Andree Blaukat
  • Aryl ether pyridazinone derivatives
    Patent number: 8445489
    Abstract: Compounds of the formula I, in which R1, R2, R3, R4, R5 and X have the meanings indicated in Claim 1, are inhibitors of tyrosine kinases, in particular Met kinase, and can be employed, inter alia, for the treatment of tumors.
    Type: Grant
    Filed: May 2, 2008
    Date of Patent: May 21, 2013
    Assignee: Merck Patent GmbH
    Inventors: Frank Stieber, Oliver Schadt, Dieter Dorsch, Andree Blaukat
  • Thiazolyl piperidine derivatives
    Patent number: 8436186
    Abstract: Compounds of the formula (I), in which R1, R2, R3, R4, R5, R6, R9, R10, R11, Q and W have the meanings indicated in Claim 1, and precursors thereof are inhibitors of sphingosine kinase and can be employed, inter alia, for the treatment of tumors.
    Type: Grant
    Filed: May 28, 2009
    Date of Patent: May 7, 2013
    Assignee: Merck Patent Gesellschaft mit beschrankter Haftung
    Inventors: Frank Stieber, Timo Heinrich, Dirk Wienke
  • 2-(heterocyclylbenzyl)pyridazinone derivatives
    Patent number: 8435981
    Abstract: Compounds of the formula (I) in which R1, R2, R3, R4 and R5 have the meanings indicated in claim 1 are inhibitors of tyrosine kinases, in particular of met kinase and can be employed inter alia for the treatment of tumors.
    Type: Grant
    Filed: July 12, 2007
    Date of Patent: May 7, 2013
    Assignee: Merck Patent Gesellschaft mit Beschränkter Haftung
    Inventors: Dieter Dorsch, Oliver Schadt, Andree Blaukat, Frank Stieber
  • Bicyclic traizole derivatives for treating of tumors
    Patent number: 8435986
    Abstract: Compounds of the formula (I), in which X1, X2, X3, X4, X5, R1, R2, R3, R3?, R4, R6 and R7 have the meanings indicated in Claim 1, are inhibitors of tyrosine kinases, in particular Met kinase, and can be employed, inter alia, for the treatment of tumours.
    Type: Grant
    Filed: July 16, 2009
    Date of Patent: May 7, 2013
    Assignee: Merck Patent Gesellschaft mit beschrankter Haftung
    Inventors: Frank Stieber, Oliver Schadt, Dieter Dorsch, Andree Blaukat